Vertex Pharmaceuticals (VRTX) Long-Term Deferred Tax (2017 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Long-Term Deferred Tax of $2.9 billion for Q1 2026, up 15.86% year-over-year from $2.5 billion in Q1 2025, and up 1.72% quarter-over-quarter from $2.9 billion in Q4 2025.
Vertex Pharmaceuticals (VRTX) Long-Term Deferred Tax (2017 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Long-Term Deferred Tax history runs 10 years deep, the most recent figure standing at $2.9 billion for Q1 2026.
- In Q1 2026, Long-Term Deferred Tax rose 15.86% year-over-year to $2.9 billion; the TTM figure through Mar 2026 stood at $2.9 billion (up 15.86% YoY), while the FY2025 annual figure was $2.9 billion, up 24.31% from the prior year.
- Long-Term Deferred Tax for Q1 2026 stood at $2.9 billion, up from $2.9 billion in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $2.9 billion in Q1 2026, with the low at $945.5 million in Q1 2022.
- The 5-year median for Long-Term Deferred Tax is $2.0 billion (2024), against an average of $2.0 billion.
- The sharpest annual moves came in 2023 and 2026: Long-Term Deferred Tax jumped 48.71% in 2023, then increased 15.86% in 2026.
- Vertex Pharmaceuticals' Long-Term Deferred Tax stood at $1.2 billion in 2022, then jumped by 45.33% to $1.8 billion in 2023, then gained by 28.64% to $2.3 billion in 2024, then gained by 24.31% to $2.9 billion in 2025, then increased by 1.72% to $2.9 billion in 2026.
- Business Quant data shows VRTX's Long-Term Deferred Tax at $2.9 billion in Q1 2026, $2.9 billion in Q4 2025, and $2.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.01 Bn |
| Mar 31, 2026 | 2.95 Bn |
| Dec 31, 2025 | 2.90 Bn |
| Sep 30, 2025 | 2.94 Bn |
| Jun 30, 2025 | 2.71 Bn |
| Mar 31, 2025 | 2.54 Bn |
| Dec 31, 2024 | 2.33 Bn |
| Sep 30, 2024 | 2.31 Bn |
| Jun 30, 2024 | 2.19 Bn |
| Mar 31, 2024 | 1.96 Bn |
| Dec 31, 2023 | 1.81 Bn |
| Sep 30, 2023 | 1.73 Bn |
| Jun 30, 2023 | 1.54 Bn |
| Mar 31, 2023 | 1.36 Bn |
| Dec 31, 2022 | 1.25 Bn |
| Sep 30, 2022 | 1.16 Bn |
| Jun 30, 2022 | 1.14 Bn |
| Mar 31, 2022 | 945.50 Mn |
| Dec 31, 2021 | 934.50 Mn |
| Sep 30, 2021 | 933.84 Mn |